phospho-CBL (Tyr774) Polyclonal Antibody, APC Conjugated
Applications
Predicted Reactivity
| Overview | |
| Catalog # | bs-3090R-APC-100uL |
| Product Name | phospho-CBL (Tyr774) Polyclonal Antibody, APC Conjugated |
| Applications |
IF(IHC-P)
IF(IHC-F)
IF(ICC)
|
| Predicted Reactivity | Human, Mouse, Rat, Sheep, Pig, Chicken, Rabbit |
| Specifications | |
| Conjugation | APC |
| Host | Rabbit |
| Source | KLH conjugated synthetic phosphopeptide derived from human CBL2 around the phosphorylation site of Tyr774 |
| Modification Site | Tyr774 |
| Clonality | Polyclonal |
| Isotype | IgG |
| Concentration | 1ug/ul |
| Purification | Purified by Protein A. |
| Storage Buffer | Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Storage Condition | Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target | |
| Gene ID | 867 |
| Subcellular location | Cell membrane |
| Synonyms | CBL2 Tyr774; CBL2 Y774; p-CBL2 Tyr774; p-CBL2 Y774; C CBL; Cas-Br-M murine ecotropic retroviral transforming sequence; Casitas B lineage lymphoma proto oncogene; CBL 2;E3 ubiquitin protein ligase CBL; Oncogene CBL2; Proto oncogene c CBL; RGD1561386; RING finger protein 55; RNF55v Signal transduction protein CBL; 4732447J05Rik; CBL_HUMAN. |
| Background | This gene is a proto-oncogene that encodes a RING finger E3 ubiquitin ligase. The encoded protein is one of the enzymes required for targeting substrates for degradation by the proteasome. This protein mediates the transfer of ubiquitin from ubiquitin conjugating enzymes (E2) to specific substrates. This protein also contains an N-terminal phosphotyrosine binding domain that allows it to interact with numerous tyrosine-phosphorylated substrates and target them for proteasome degradation. As such it functions as a negative regulator of many signal transduction pathways. This gene has been found to be mutated or translocated in many cancers including acute myeloid leukaemia. Mutations in this gene are also the cause of Noonan syndrome-like disorder. [provided by RefSeq, Mar 2012] |
| Application Dilution | |
| IF(IHC-P) | 1:50-200 |
| IF(IHC-F) | 1:50-200 |
| IF(ICC) | 1:50-200 |
Frequently asked questions
Which applications is phospho-CBL (Tyr774) Polyclonal Antibody, APC Conjugated (bs-3090R-APC) validated for, and at what dilution?
bs-3090R-APC is validated for IF(IHC-P) (1:50-200); IF(IHC-F) (1:50-200); IF(ICC) (1:50-200). These are recommended starting dilutions; optimal dilutions should be determined by the end user.
How should bs-3090R-APC be stored?
Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. Storage buffer: Aqueous buffered solution containing 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
What immunogen was used to raise phospho-CBL (Tyr774) Polyclonal Antibody, APC Conjugated (bs-3090R-APC)?
KLH conjugated synthetic phosphopeptide derived from human CBL2 around the phosphorylation site of Tyr774
What are the excitation and emission wavelengths of the APC conjugate (bs-3090R-APC)?
APC on bs-3090R-APC: excitation / emission 650nm/660nm.